Restoring Enzyme Function in Lysosomal Storage Diseases with Calcium Channel Blockers
Author Information
Author(s): Mu Ting-Wei, Fowler Douglas M, Kelly Jeffery W
Primary Institution: The Scripps Research Institute
Hypothesis
Can manipulating calcium homeostasis improve the function of mutant lysosomal enzymes in lysosomal storage diseases?
Conclusion
Diltiazem and verapamil can partially restore the function of mutant lysosomal enzymes in three distinct lysosomal storage diseases by enhancing their folding and trafficking.
Supporting Evidence
- Diltiazem and verapamil are FDA-approved drugs that enhance the folding and trafficking of mutant lysosomal enzymes.
- Calcium channel blockers can improve enzyme homeostasis in multiple lysosomal storage diseases.
- Manipulating calcium levels in cells can help restore function to misfolded proteins.
Takeaway
Some medicines can help sick cells work better by fixing how they handle proteins, which is important for certain diseases.
Methodology
The study used patient-derived fibroblast cell lines to assess the effects of diltiazem and verapamil on mutant enzyme activity.
Limitations
Further studies are needed to confirm clinical utility and safety of the treatments.
Participant Demographics
Fibroblast cell lines from patients with Gaucher disease and other lysosomal storage diseases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website